Incyte raises 2026 net sales forecast to $5.21 billion-$5.3 billion
Bitget2026/10/29 12:13- Incyte raised its 2026 net sales forecast to $5.21 billion-$5.3 billion from $5.13 billion-$5.26 billion.
- Opzelura sales guidance increased to $1.1 billion-$1.12 billion from $1.05 billion-$1.1 billion.
- Hematology and oncology sales are now projected at $890 million-$910 million, up from $860 million-$890 million.
- Jakafi sales guidance remained unchanged at $3.22 billion-$3.27 billion.
- Third-quarter net sales rose 14% to $1.32 billion; sales excluding Jakafi increased 37% to $490 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Production Increase Falls Short, Layoffs First! Boeing (BA.US) Cuts 5% of Commercial Airplane Jobs, Delays 737 Monthly Production Target of 47 Aircraft to 2027
Stephanie Pope, head of Boeing's commercial airplanes division, informed employees in an internal memo on Monday that due to obstacles in increasing aircraft production, the division plans to cut 5% of its workforce.
Crypto prices
More
